Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink.

Authors:
Kenigsberg TA; Hanson KE; Klein NP; Zerbo O; Goddard K and 8 more

Journal:
Vaccine

Publication Year: 2023

DOI:
10.1016/j.vaccine.2023.06.042

PMCID:
PMC10267508

PMID:
37344264

Journal Information

Full Title: Vaccine

Abbreviation: Vaccine

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"appendix a supplementary material the following are the supplementary data to this article: supplementary data 1 data availability the authors do not have permission to share data."

Code Sharing
Evidence found in paper:

"Conflict of interest disclosures KEH reports research support from Seqirus for unrelated studies. NPK reports research support from Pfizer for COVID vaccine clinical trials and from Merck, Pfizer, GlaxoSmithKline and Sanofi Pasteur for unrelated studies. WKY has received research funding from Pfizer in the past. All other co-authors have no conflicts of interest to report. Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Kayla E. Hanson reports a relationship with Seqirus that includes: funding grants. Nicola P. Klein reports a relationship with Pfizer that includes: funding grants. Nicola P. Klein reports a relationship with Merck & Co Inc that includes: funding grants. Nicola P. Klein reports a relationship with GlaxoSmithKline that includes: funding grants. Nicola P. Klein reports a relationship with Sanofi Pasteur that includes: funding grants. W. Katherine Yih reports a relationship with Pfizer that includes: funding grants."

Evidence found in paper:

"Funding/support This work was supported by the Centers for Disease Control and Prevention (CDC). This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy. See, for example, 45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C. §3501 et seq."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025